These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. What defines the quality of patient care in tinea pedis? Mistik S, Ferahbas A, Koc AN, Ayangil D, Ozturk A. J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):158-65. PubMed ID: 16441623 [Abstract] [Full Text] [Related]
7. A novel mycological analysis valuable for evaluating therapeutic efficacy of antimycotics against experimental dermatophytosis in guinea pigs. Majima T, Masui S, Uchida K, Yamaguchi H. Mycoses; 2005 Mar; 48(2):108-13. PubMed ID: 15743427 [Abstract] [Full Text] [Related]
12. In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China. Li RY, Wan Z, Wang AP, Shen YN, Lu CM, Li M, Xi LY, Liu WD, Zeng FQ. Mycoses; 2004 Oct; 47(9-10):402-6. PubMed ID: 15504124 [Abstract] [Full Text] [Related]
13. In vitro and in vivo antidermatophytic activity of saperconazole, a new fluorinated triazole. Fu KP, Isaacson DM, Lococo J, Foleno B, Hilliard J. Drugs Exp Clin Res; 1992 Oct; 18(11-12):443-6. PubMed ID: 1308468 [Abstract] [Full Text] [Related]
19. Anti-dermatophytic activity of bakuchiol: in vitro mechanistic studies and in vivo tinea pedis-inhibiting activity in a guinea pig model. Lau KM, Wong JH, Wu YO, Cheng L, Wong CW, To MH, Lau CP, Yew DT, Leung PC, Fung KP, Hui M, Ng TB, Lau CB. Phytomedicine; 2014 Jun 15; 21(7):942-5. PubMed ID: 24703327 [Abstract] [Full Text] [Related]